News
XOMA
28.66
+0.21%
0.06
Weekly Report: what happened at XOMA last week (0909-0913)?
Weekly Report · 2d ago
Weekly Report: what happened at XOMA last week (0902-0906)?
Weekly Report · 09/09 11:44
XOMA Royalty to Present at Upcoming Investor Conferences in September
Barchart · 09/04 06:30
Weekly Report: what happened at XOMA last week (0826-0830)?
Weekly Report · 09/02 11:48
Weekly Report: what happened at XOMA last week (0819-0823)?
Weekly Report · 08/26 11:45
Weekly Report: what happened at XOMA last week (0812-0816)?
Weekly Report · 08/19 11:29
Risinger Affirms Buy Rating on Xoma with Increased Price Target Amid Strong Financial Performance and Unrecognized Asset Potential
TipRanks · 08/16 06:37
XOMA Price Target Raised to $117.00/Share From $74.00 by HC Wainwright & Co.
Dow Jones · 08/15 10:31
HC Wainwright & Co. Maintains Buy on XOMA Royalty, Raises Price Target to $117
Benzinga · 08/15 10:22
Buy Rating Affirmed: Xoma’s Strategic Growth and Financial Strength Highlighted
TipRanks · 08/14 10:29
XOMA ROYALTY CORP <XOMA.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $49 FROM $42
Reuters · 08/14 10:06
TD Cowen Keeps Their Hold Rating on Xoma (XOMA)
TipRanks · 08/13 18:26
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
Investorplace · 08/13 17:54
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
TipRanks · 08/13 14:10
XOMA Royalty Corp reports results for the quarter ended in June - Earnings Summary
Reuters · 08/13 12:29
XOMA Royalty Corporation Quarterly Report (Form 10-Q)
Press release · 08/13 12:17
XOMA GAAP EPS of $0.84, revenue of $11.1M
Seeking Alpha · 08/13 11:49
*XOMA Royalty 2Q Net $16M >XOMA
Dow Jones · 08/13 11:36
*XOMA Royalty 2Q EPS 84c >XOMA
Dow Jones · 08/13 11:33
XOMA CORP - QTRLY SHR $0.84
Reuters · 08/13 11:30
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).